NCT00745186View on ClinicalTrials.gov

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

March 31, 2008

Conditions

Hypoglycemia

Interventions

DRUG

Glucagen

0.2 mg or 1 mg Glucagen single injection

DRUG

Mayne Glucagon

0.2 mg or 1 mg Mayne Glucagon

Trial Locations (1)

EH14 4AP

Charles River Laboratories, Edinburgh

All Listed Sponsors

lead

Hospira, now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00745186 - Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers | Biotech Hunter | Biotech Hunter